NORDIC NANOVECTOR ASA – MANDATORY NOTIFICATION OF TRADE/ISSUANCE OF NEW SHARES

 

Rita Dege, Chief Human Resources Officer has exercised 3,000 options in Nordic Nanovector ASA (the "Company"), corresponding to 3,000 shares at a strike price of NOK 28 per share. The board of directors of the Company has pursuant to the authorisation granted to board of directors at the annual general meeting in 2016, resolved to issue 3,000 new shares at a subscription price of NOK 28 per share to Rita Dege. The Company will following the issuance of the new shares have a share capital of NOK 8,920,074.80 divided on 44,600,374 shares, each with a nominal value of NOK 0.20 per share.

After the exercise of the options, Rita Dege owns 3,000 shares in the Company and Rita Dege holds 32,000 options in the Company.

This information is subject to duty of disclosure pursuant to section 4-2 of the Norwegian Securities Trading Act and section 3.2 of the Continuing Obligations listed companies.

 

 

Tags:

About Us

About Nordic Nanovector ASA Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.Further information about the Company can be found at www.nordicnanovector.com

Subscribe